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Solution growth and thermal treatment of crystals
lead to two new forms of 2-((2,6-dimethylphenyl)
amino)benzoic acid†
Rong Hu,‡a Yunping Zhoujin,‡a Meng Liu,a Mingtao Zhang,b Sean Parkin,d
Panpan Zhou, c Jianzhi Wang,a Faquan Yu*a and Sihui Long *a
We report the discovery of two new forms (II and III) of a potential non-steroidal anti-inflammatory and
thyroid drug, 2-((2,6-dimethylphenyl)amino)benzoic acid (HDMPA) through solution growth and thermal
treatment of crystals. Form II has been discovered through crystal growth in a variety of solvents, and
characterized by single-crystal X-ray diffraction, powder X-ray diffraction (PXRD), FT-IR, and Raman
spectroscopy. Form II converts into form III upon thermal treatment, as indicated by the phase behavior
study of form II with differential scanning calorimetry (DSC). Form III has been characterized by IR,
Raman and PXRD. Conformational flexibility of the molecule seems to lead to the polymorphism of the
system. A conformational scan shows the conformational minima correspond to the conformers in the
polymorphs. Lattice energy calculations show energies of 48.14 and 50.31 kcal mol1 for forms I and
II, providing information on the relative stability for each form. Hirshfeld analysis revealed that
intermolecular interactions such as C/C, H/H, C/H, and H/O contribute to the stability of the crystal
forms.
1. Introduction
N-Anthranilic acids, the nitrogen isosteres of salicylic acid,
constitute an important class of non-steroidal anti-
inammatory drugs (NSAIDs).1 Classic anthranilic acid
NSAIDs include mefenamic acid, meclofenamic acid, chlofe-
namic acid, and other structurally related compounds.2 Their
medical application is not limited to NSAIDs, and they can also
be used as analgesics and antirheumatics.1 Recently, this class
of compounds have been investigated as therapeutics for
neurodegenerative and amyloid diseases as well as cancer, and
some have shown great promise.3–5 At the same time, these
compounds can be used as ligands in inorganic complexes in
the search for anticancer drugs.6 In addition, fenamic acids are
also synthetic precursors to acridones and acridines, which
present bioactive properties such as anti HIV, anticancer, anti-
bacterial, antifungal, and antimalarial activities.7
Likely due to their intrinsic conformational exibility (as
diarylamines), N-anthranilic acids tend to be polymorphic, i.e.,
existing in more than one crystal form. Several important N-
anthranilic acid NSAIDs have multiple crystal forms. For
example: two, ve, nine, two, and four forms have been found
for mefenamic acid,8 tolfenamic acid,9 ufenamic acid,10 niu-
mic acid,11 and clonixin,12 respectively. The existence of nine
forms of ufenamic acid is reported to be the current world
record for most forms having been structurally characterized by
single-crystal X-ray diffraction. Recently, clonixin was found to
form a solvate with N,N-dimethylformamide.13 Polymorphism is
important both theoretically (CSP)14,15 and practically.16–19 Poly-
morphism is of particular signicance in pharmaceuticals
because different forms of the same API (Active Pharmaceutical
Ingredient) may have different kinetic, thermodynamic,
surface, mechanical, and packaging properties, which can affect
clinical formulation and eventual bioavailability.20,21
HDMPA is an N-anthranilic acid similar to other NSAIDs
with potent anti-inammatory properties.22 In addition, it has
ramications in the treatment of disorders caused by thyroid
hormone excess by inhibiting triiodothyronine uptake by the
hepatocytes.23
In 2004, in an attempt to synthesize phenylorganotin
complexes as anti-tuberculosis drugs, Dokorou et al. discovered
the rst crystal structure of HDMPA (designated form I). The
asymmetric unit of form I consists of two crystallographically
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independent molecules (Z0 ¼ 2) and the two molecules are
distinct in geometry.24
Our lab has been interested in the polymorphism of diaryl-
amines for the past decade. We have systematically investigated
a series of compounds using a combination of both experi-
mental and theoretical approaches.25–29 Recently we also studied
the polymorphism of an important N-anthranilic acid, 4-chloro-
phenylanthranilic acid and highlighted the role played by both
the conformational exibility and sp2 C–H/Cl hydrogen
bond.30
In this study, we report the discovery and characterization of
a 2nd form of HDMPA, as well as the structural comparison of
forms I and II, and the generation and characterization of
a third form (III) of the compound, and the corresponding




All solvents and reagents were purchased from commercial
sources and used as received: 2-chlorobenzoic acid was from
J&K Chemical (Beijing, China), 2,6-dimethylaniline was from
Energy Chemical (Shanghai, China), and Cu2O was from
Aladdin (Shanghai, China); Cu, K2CO3, 2-ethoxyethanol, and the
solvents used for crystal growth were from Sinopharm Chemical
Reagent Co., Ltd (Shanghai, China). The IR and Raman spectra
were recorded using an FT-IR Perkin-Elmer LX10-8873 and
a Thermo Electron DXR Laser Confocal Microscopy Raman
Spectrometer, respectively. NMR spectra were obtained on
a Varian INOVA spectrometer at an observation frequency of 400
MHz. Thermal analyses were performed on an SII DSC 6220
(SEIKO, Japan) apparatus, using a heating rate of 10 C min1.
2.2. Synthesis and characterization
2.2.1 Synthesis of 2-((2,6-dimethylphenyl)amino)benzoic
acid.31 2-Chlorobenzoic acid (1.38 g, 8.8 mmol), 2,6-dimethyl-
phenylamine (1.13 g, 9.3 mmol), Cu (50.0 mg, 0.8 mmol),
Cu2O (57.2 mg, 0.4 mmol) and K2CO3 (1.25 g, 8.8 mmol) were
added to a round-bottom ask, followed by addition of 2-
ethoxyethanol (3 mL) under nitrogen protection. The resulting
mixture was reuxed at 130 C for 24 h. The hot reaction
mixture was poured into 30 mL of room temperature water. The
insoluble components were removed by ltration. The crude
product was obtained by precipitation upon acidication of the
ltrate with dilute HCl. The product was puried on a silica-gel
column using petroleum ether/ethyl acetate (v/v 100 : 1,
Rf ¼ 0.50) as eluent. The product was obtained as colorless solid
(230 mg, yield%: 11) (Scheme 1).
1H-NMR (400 MHz, CDCl3): d ppm 8.90 (s, 1H), 8.05 (d, 1H),
7.26 (t, 1H), 7.16 (s, 3H), 6.67 (t, 1H), 6.29 (d, 1H), 2.23 (s, 6H);
13C-NMR (100 MHz, CDCl3): d ppm 174.2, 150.7, 136.9, 135.6,
132.5, 129.1, 128.0, 127.3, 128.3, 115.8, 112.7, 108.7, 18.2; IR
(KBr, cm1) 3346 (s), 3018–2539 (m), 1651 (s), 1578 (s), 1498(s),
1417 (s), 1250 (s), 1170 (s), 923 (m), 785 (s), 741 (s); MS (ESI):
242.1 (M + 1); mp: 208 C.
Scheme 1 Synthesis of HDMPA.
Table 1 Crystal growth of HDMPA in different solvents
Solvents Method Form
Acetone Slow evaporation II
Chloroform Slow evaporation II
Ethyl acetate Slow evaporation II
Methanol Slow evaporation II
Dichloromethane Slow evaporation II
Ethanol Slow evaporation II
Hexane Slow evaporation II
Pet ether Slow evaporation II
Acetonitrile Slow evaporation II
Ether Slow evaporation II
iso-Propanol Slow evaporation II
Dimethyl sulfoxide Slow evaporation II
Tetrahydrofuran Slow evaporation II
Dimethylformamide Slow evaporation II
Toluene Slow evaporation II
Benzene Slow evaporation II
Acetic acid Slow evaporation II
Tetrahydrofuran & acetone (1 : 1) Slow evaporation II
Tetrahydrofuran & acetone (various ratios) Quench cooling II
Fig. 1 Labeling of HDMPA.


























































































Slow evaporation was applied for polymorph screening of
HDMPA.32 The experiment is as follows: pure HDMPA was dis-
solved in eighteen different solvents (the compound is insoluble
in water), forming saturated solutions at ambient temperature
(22 C) (Table 1). The solutions were set to evaporate in
a vibration-free environment until single crystals appeared or
no solvent remained. For example, 50 mg of HDMPA was sus-
pended in 5 mL HPLC grade acetonitrile. The mixture was
agitated overnight and the remaining solid was pipette ltered.
A vial containing the saturated solution was covered with
perforated paralm. Slow evaporation led to single crystals in
about a week. Quench cooling was used to obtain form I, as
reported in the literature. For quench cooling, a supersaturated
solution of HDMPA in a mixture of THF and acetone (1 : 1 ratio)
at 50 C was rapidly cooled in a freezer of 20 C. All crystalli-
zation experiments were conducted in an unmodied atmo-
sphere. Each experiment was repeated multiple times. All
experiments led to crystal form II. The crystals were identied
by single-crystal X-ray diffraction when high-quality single
crystals were available, and by powder X-ray diffraction for tiny
crystals.
2.4. Crystal structure determination
The crystal structures of form II HDMPA were determined by
single-crystal X-ray diffraction at both 90 K (low temperature,
LT) and 296 K (room temperature, RT).
Data collection was carried out at 90 K on a Nonius kap-
paCCD diffractometer with MoKa radiation (l ¼ 0.71073 Å),33
and at 296 K on a Bruker SMART APEX II diffractometer.
Cell renement and data reduction were done using SCA-
LEPACK and DENZO-SMN for the low temperature structure,34
and SADABS and Bruker SMART for the room temperature
structure. Structure solution and renement were carried out
using the SHELXS and SHELXL2016 programs, respectively.35,36
Powder X-ray diffraction (PXRD) data for each sample were
collected on a Rigaku X-ray diffractometer with CuKa radiation
(40 kV, 40 mA, l ¼ 1.5406 Å) between 5.0–50.0 (2q) at ambient
temperatures. The nely ground sample was placed on a quartz
plate in an aluminum holder.
2.5. Thermal analyses
Phase behavior for the solid forms were studied by differential
scanning calorimetry (DSC), vide supra.
2.6. Spectroscopic studies
For IR spectrum recording, samples were dispersed in KBr
pellets. For Raman measurement, samples were compressed in
a gold-coated sample holder.
2.7. Computational details
2.7.1 Conformation search. Based on the structure, bonds
C2–C14, C1–N7 and N7–C8 (Fig. 1) are potential causes of the
conformational exibility. Nevertheless, we only evaluated
the energy of different conformations of a single HDMPA







II (RT) 1.375 1.441
II (LT) 1.378 1.441
Fig. 2 SEM micrographs of crystals of HDMPA form II from different solvents and form III.

























































































molecule dened by the torsion angle C1–N7–C8–C9 (s), with
Gaussian 09 (Gaussian, Inc., Wallingford, CT), because C1–
N7 has a bond length of 1.38 Å, indicating a double bond
(which precludes rotation), and the carboxylic acid group in
all conformers is coplanar with the aromatic ring in spite of
the single-bond character for C2–C14 bond (C–C ¼ 1.47 Å)
(Table 2). The molecule was optimized from various initial
structures in order to identify the most stable conformation,
which was then used for scanning each torsion angle with all
bond lengths, bond angles, and other torsion angles xed.
The B3LYP/6-311+G(d, p) level of theory was applied for the
structural optimization and conformational search.
2.7.2 Lattice energy. To calculate the lattice energy for
each HDMPA form, we rst optimized the experimental
crystal structures with the lattice parameters xed. The
optimization was conducted by DFT using the PW1PW
Table 3 Crystallographic data of HDMPA polymorphs I and II (LT, low temperature, determined at 90 K; and RT, room temperature, determined
at 296 K)
I II (LT) II (RT)
Formula C15H15NO2 C15H15NO2 C15H15NO2
Formula weight 241.28 241.28 241.28
Crystal size (mm) 0.50  0.50  0.15 0.30  0.20  0.20
Crystal system Triclinic Triclinic Triclinic
Space group P1 P1 P1
a/Å 15.8375(16) 7.4127(1) 7.524(2)
b/Å 7.5311(7) 8.0298(1) 8.103(2)
c/Å 11.1845(12) 10.9583(2) 11.191(3)
a/ 83.728(9) 73.3544(8) 72.582(4)
b/ 104.806(9) 83.3366(8) 83.740(4)
g/ 79.038(8) 73.6078(8) 73.854(2)
Z, Z0 4, 2 2, 1 2, 1
V/Å3 1248.560 599.091(16) 625.1(3)
Dcal/g cm
3 1.284 1.338 1.276
T/K 296 90(2) 296(2)
Abs. coeff. (mm1) 0.089 0.085
F(000) 256 254
Range (deg) 1.94–27.49 1.91–25.00
Limiting indices 9 # h # 9 6 # h # 8
10 # k # 10 9 # k # 9
14 # l # 14 13 # l # 12
Completeness to 2q 99.5% 98.5%
Unique reections 2737 2170
R1[I > 2s(I)] 0.0553 0.0434 0.0490
wR2 (all data) 0.0553 0.1190 0.1552
Fig. 3 Superposition of all three molecular conformations in the asymmetric units of forms I and II of HDMPA.

























































































functional with 6-21g** basis sets by Crystal14.37 We also
calculated the dispersion energy contributions to lattice
energies using the DFT-D3 program of Grimme, with Becke–
Johnson damping.38,39 We considered the basis set
superposition error (BSSE) by the counterpoise method.40
The energy convergence of the optimization and energy
calculation was set to 107 hartree. The root-mean-square
(RMS) values for calculation convergence were set to 0.0003
Fig. 4 Crystal packing of I and II. For clarity, only hydrogens involved in hydrogen bonds (dotted line) are shown.
Fig. 5 DSC thermograms of HDMPA form II before and after thermal treatment.

























































































and 0.0012 au for energy gradient and atomic displacement,
respectively. All calculations were conducted on a Linux
cluster.
2.7.3 Hirshfeld surface analysis. We performed Hirshfeld
surface analyses41,42 with CrystalExplorer (Version 3.1)43 to
account for the relative contributions to intermolecular inter-
actions by various molecular contacts in the polymorphs.
Fig. 6 PXRD patterns of HDMPA form II before and after thermal treatment.
Fig. 7 Experimental and calculated PXRD patterns of HDMPA polymorphs.

























































































3. Results and discussion
3.1. Crystal structures
Two new polymorphs (II and III) of HDMPA have been discov-
ered in this study (Fig. 2). Form II crystals were grown as
colorless blocks from (but not limited to) acetone, and form III
was generated upon thermal treatment of form II samples.
Form I crystals were obtained as colorless plates from a mixture
of THF and acetone.24 Structure determination by single-crystal
X-ray diffraction found form II to be triclinic, space group P (Z¼
2), and form I was reported to be triclinic, space group P (Z¼ 4).
No single crystal structure was determined for form III. Crys-
tallographic data for form I and two structures of form II are
given in Table 3; for complete CIF les, see the ESI.† The crys-
tallographically independent conformations in each of the
asymmetric units are slightly different, as suggested by the
dihedral angle between the two aromatic rings (88.25(38) for I-
A and 86.69(34) for I-B in form I, 88.91(4) for II in form II).
Conformational variability is also shown by a superposition of
all three experimental conformations (Fig. 3).
In form I, the asymmetric unit consists of two molecules
(Z0 ¼ 2), each having a twisted conformation. The twomolecules
form an acid–acid dimer hydrogen-bonding motif (R22(8)).44–46
The intermolecular hydrogen bond has a bond distance and
bond angle of 1.888 Å and 138.28 for O16–H16/O15 for
molecule A, and 1.830 Å and 140.31 for O16–H16/O15 for
molecule B. In addition to the intermolecular hydrogen bonds,
an intramolecular hydrogen bond exists between the carboxylic
acid carbonyl O and the NH bridging the two aromatic rings,
with a bond distance of 2.140 Å and bond angle 119.94 for
molecule A and 2.071 Å and 120.79 for molecule B (Fig. 4).
Form II has one molecule in the asymmetric unit (Z0 ¼ 1),
and the molecule shows a twisted conformation, with the
aromatic rings being perpendicular, as suggested by a dihedral
Fig. 8 IR spectra of the new forms of HDMPA.
Table 4 Characteristic IR peaks of the new forms of HDMPA
N–H stretch Carboxyl O–H stretch and aromatic/aliphatic C–H stretch Carboxyl C]O stretch Aromatic C]C stretch
Form II 3339.5 3031.7–2565.3 1650.8 1596.6
1572.9
1500.1
Form III 3343.3 3077.6–2561.0 1658.4 1595.0
1572.5
1501.8

























































































angle of 88.91(4). The molecules form centrosymmetric acid–
acid dimers. The intermolecular hydrogen bond has a bond
distance and bond angle of 1.684 Å and 174.34 for O16–H16/
O15. Both the bond distance and bond angle are signicantly
different from those in form I. The intramolecular hydrogen
bond between the carbonyl O of the carboxylic acid and the
anilino NH has a bond distance of 2.020 Å and bond angle of
135.16. The intramolecular hydrogen bond parameters are also
different from those in form I.
An exhaustive polymorph screening was performed to obtain
the literature form I, yet only the new form II was generated.
Questions were raised on the authenticity of the literature form.
Simulated PXRD patterns are almost identical between forms I
and II. But disappearing polymorphism could be the reason of
the absence of form I.47
3.2. Thermal properties
DSC was conducted to investigate the thermal properties of
form II, shown in Fig. 5. Form II has two endothermic DSC
peaks. The rst, with an onset temperature of 199.2 C, appears
to be a phase transition to a new form that melts at approxi-
mately 201.6 C. Based on the DSC thermograms, we can infer
that form II converts into a third form when heated. As
mentioned before, form I has Z0 ¼ 2 and form II has Z0 ¼ 1 and
most of the time, the Z0 ¼ 1 form is more stable than the high Z0
forms,48,49 so it is unlikely that form II transforms into form I,
suggesting that the new form (labelled III above) could be
a third form.
We also investigated the reversibility of the phase transition.
When the sample was heated to a temperature just below the
Fig. 9 Raman spectra of HDMPA polymorphs.
Table 5 Characteristic Raman peaks of the new forms of HDMPA
N–H stretch Carboxyl O–H stretch and aromatic/aliphatic C–H stretch Carboxyl C]O stretch Aromatic C]C stretch
Form II 3340.6 3090.5–2919.0 1621.5 1591.4
1578.3
1401.2
Form III 3343.4 3079.4–2919.4 1623.7 1592.5
1578.0
1408.2

























































































melting (200 C) and then cooled down to room temperature,
the DSC of the new sample showed only one peak, which
corresponds to the melting of the sample. PXRD was measured
for form III. The patterns of form III is different from that of
form II as shown in Fig. 6.
Fig. 7 shows the calculated powder X-ray diffraction patterns
of forms I and II collected at room temperature (a), along with
the matching of PXRD patterns calculated from the single-
crystal structures determined at both 90 K and 296 K and the
experimental PXRD patterns. The calculated PXRD patterns of
the literature form and the new form are nearly identical, and
the experimental and calculated PXRD patterns for form II
match extremely well.
3.2.1 Spectroscopic characteristics. IR spectra of the two
new forms of HDMPA are shown in Fig. 8. They show similar IR
spectra, but subtle differences are observed as indicated in
Table 4.
The vibrational spectra show the effect of the intramolecular
hydrogen bond between NH and O]C. The NH stretch is at
a lower frequency of around 3339.5 and 3343.3 cm1 for forms II
and III, respectively. The carboxyl C]O stretch is at 1650.8 and
1658.4 cm1 for forms II and III. The carboxyl O–H and
aromatic/aliphatic C–H as well as aromatic C]C stretches show
subtle differences between forms II and III as indicated in
Table 4.
The Raman spectra of the two new forms of HDMPA were
measured for comparision (Fig. 9). Subtle yet distinguishable
differences are observed (Table 5).
The Raman spectra also show the effect of the intra-
molecular hydrogen bond between NH and O]C. The NH
stretch is at a lower frequency of around 3340.6 and
3343.4 cm1, and the carboxyl C]O stretch is at 1621.5 and
1623.7 cm1 for forms II and III, respectively. The carboxyl O–H
and aromatic/aliphatic C–H as well as aromatic C]C stretches
also show subtle differences between forms II and III as indi-
cated in Table 5.
3.3. Computational results
For forms I and II, calculated lattice energies based on the
empirically augmented DFT method are 48.14 and
50.31 kcal mol1. The energy difference between forms I and
II is 9.07 kJ mol1, slightly higher than 6 kJ mol1, which is in
agreement with the observation that conformational poly-
morphs have higher lattice energy differences.50 Two forms have
similar calculated densities at 296 K (I: 1.284 g cm3 and II:
1.276 g cm3). While form I is slightly denser than form II, its
lattice energy is higher than that of form II, which might be due
to the hydrogen bond difference between the two forms, since
form II has a shorter and more linear hydrogen bond than form
I. Due to the uncertainty inherent to the computational
methods employed (which may range from a few kJ mol1 to
a few kcal mol1, or even higher), the small energy difference
between forms I and II should not be regarded as evidence of
which is more stable. Also it should be pointed out that
Fig. 10 Conformation scan of single HDMPA molecule.
































































































discrepancy could arise since the computation implicitly
assumed a temperature of 0 K, whereas the densities are based
on the structures measured at 296 K, and the DSC experiments
were performed at elevated temperatures.
Although steric hindrance can limit the exibility of HDMPA,
polymorphism could arise from its intrinsic conformational
exibility. The conformational scan conducted over s for
a single HDMPA molecule is illustrated in Fig. 10. The global
minima of s are identied at 78.5 and 98.0 due to the
symmetry of the benzene ring. The conformers of both forms
are located near the minima, but in two different energy valleys.
Thus it appears that the polymorphic system is one of confor-
mational polymorphism, not merely due to conformational
adjustment.51 The torsion angle of all three conformations is
listed in Table 6.
3.3.1 Hirshfeld surface analysis. As shown in Fig. 11, the
Hirshfeld analysis results indicate that in all six potential
molecular contacts, hydrogen–hydrogen contacts predominate,
contributing 60.5 and 59.9% of the overall intermolecular
interactions in forms I and II, respectively. The second most
signicant intermolecular interaction is C/H, resulting in 18.6
and 19.0% of the sum of intermolecular interactions in the
individual forms. In addition, H/O interactions also
contribute signicantly to the total intermolecular interactions,
being 15.2 and 15.1% in forms I and II. Taken together, the
crystal structures were stabilized by a variety of interactions.
4. Conclusions
Two new forms have been discovered for HDMPA, a fenamic
acid with potential as an NSAID and in treatment of thyroid
hormone disorders. Form II was characterized by structure
determination by single-crystal X-ray diffraction, PXRD and
spectroscopic methods such as FT-IR and Raman. The poly-
morphism appears to result from the conformational exibility
of the molecule, as suggested by the conformers in the two
modications and the conformational scan. The phase behav-
iors of the new forms were studied by DSC. The metastable form
II appears to convert into form III on the application of thermal
energy. Form III was characterized by PXRD, FT-IR and Raman
spectroscopy. Lattice energies were calculated to be 48.14 and
50.31 kcal mol1 for forms I and II suggesting the relative
Fig. 11 Hirshfeld surface analysis of the two forms of HDMPA, (a) form II; and (b) form I.

























































































stabilities of the polymorphs, and Hirshfeld analysis indicated
intermolecular interactions such as H/H, C/H, and H/O
contribute signicantly to the overall stability of the forms. This
study clearly indicates that thermal treatment of crystalline
samples could be an efficient approach for new polymorph
generation. We are currently attempting to obtain single crys-
tals for form III.
Conflicts of interest
There are no conicts to declare.
Acknowledgements
RH and SL thanks Natural Science Foundation of Hubei Prov-
ince (2014CFB787) and the President's Fund of Wuhan Institute
of Technology (CX2016075) for nancial support. PPZ
acknowledges the nancial support by the National Natural
Science Foundation of China (Grant No. 21403097) and the
Fundamental Research Funds for the Central Universities
(lzujbky-2016-45).
References
1 S. Bajaj, S. S. Sambi and A. K. Madan, Bioorg. Med. Chem.,
2004, 12, 3695.
2 J. S. Kaltenbronn, R. A. Scherrer, F. W. Short, E. M. Jones,
H. R. Beatty, M. M. Saka, C. V. Winder, J. Wax and
W. R. Williamson, Arzneim. Forsch., 1983, 33, 621.
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